Ben Auspitz Email & Contact Information
Venture Partner @ Forge Life Science Partners
Show Ben's emailBen Auspitz Location
Cambridge, United States
Ben Auspitz Work
- 2025–nowManaging Partner, Breakout Fund @ Curie.Bio
- 2025–nowVenture Partner @ Forge Life Science Partners
- 2024–2025Chairman of the Board @ IDRx
- 2022–2025Managing Partner, Founder @ Forge Life Science Partners
See more
- 2021–2024Chief Executive Officer, Founder @ IDRx
- 2005–2021Partner @ F-Prime Capital
- 2018–2019Chairman of the Board @ Modis Therapeutics
- 2015–2018Chairman of the Board, Founder @ Orchard Therapeutics
- 2013–2015Chairman of the Board, Founder @ Dimension Therapeutics
- 2011–2014Director @ Ultragenyx Pharmaceutical Inc.
- 2001–2005Therapeutic Area Director, @ CombinatoRx
- 1999–2000consultant @ Braun Consulting
- 1995–1997Consultant @ Vertex Partners
Ben Auspitz Investing
Venture Partner at Forge Life Science Partners
- Stages
- Series A
- Sectors
- Health tech
- Cheque size
- €92k–€9.2M
- Freshness
- Verified 1mo ago
Ben Auspitz Summary
Ben Auspitz, based in Cambridge, United States, is a Venture Partner at Forge Life Science Partners. Ben Auspitz invests in Health tech at Series A, writing €92k–€9.2M cheques. Ben Auspitz brings experience from Curie.Bio, IDRx, F-Prime Capital and Modis Therapeutics. Ben Auspitz's verified email and contact details are available on Mintround.
How to cold email Ben Auspitz
Ben Auspitz, Forge Life Science Partners in Cambridge, United States, backs Health tech companies at Series A, writing €92k–€9.2M cheques. Here's how to get a reply when you cold email Ben:
- Subject line: name your company and one metric that matters to Health tech, not “quick chat”.
- First line: your strongest traction, the real numbers, not adjectives.
- One ask: a 20-minute call with a date range. Keep it under 150 words.
- Send it to Ben's verified address below. No warm intro required.
Every contact is a verified, deliverable email. How Mintround verifies contacts.
Are you Ben Auspitz? Request removal of this listing.